Sorrento Therapeutics Inc

NASDAQ:SRNE   3:59:56 PM EDT
7.91
-0.17 (-2.10%)
Products, Regulatory

ANVISA Authorizes Sorrento's Phase 2 Clinical Trial Of Abivertinib In COVID-19 Patients

Published: 10/14/2020 16:02 GMT
Sorrento Therapeutics Inc (SRNE) - Brazilian Health Regulatory Agency (anvisa) Authorizes Sorrento Therapeutics’ Large Phase 2 Clinical Trial of Abivertinib in Mild, Moderate and Severe Covid-19 Patients.
Sorrento Therapeutics Inc - Phase 2 Clinical Trials of Abivertinib Now Cleared to Proceed in Both Brazil and U.S.sorrento Therapeutics - Brazilian Study is Expected to Rapidly Enroll 400 Patients.